向阿波利波蛋白C-III的RNA干扰疗法在高甘油三血症中
Daniel Gaudet1, Peter Clifton2, David Sullivan3
1Department of Medicine, Université de Montréal and ECOGENE 21 Clinical Research Center, Chicoutimi, Quebec, QC, Canada.
NEJM evidence
|February 6, 2024
概括
作为一种RNA干扰疗法,ARO-APOC3有效降低了阿波利波蛋白C-III (APOC3) 和高甘油三水平在患有高甘油三血症的参与者中. 在这项短期研究中,该疗法表现出了有利的安全性概况,几乎没有不良事件.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 阿波利波蛋白C-III (APOC3) 通过抑制脂蛋白脂酶和肝细胞吸收富含甘油三脂蛋白来降低甘油三清除.
- ARO-APOC3是一种RNA干扰疗法,针对APOC3mRNA降低甘油三水平.
研究的目的:
- 评估ARO-APOC3的安全性,药理动力学和药理动力学在健康个体和患有高甘油三血的人群中.
- 评估ARO-APOC3在降低APOC3和甘油三水平方面的有效性.
主要方法:
- 一个随机,双盲,安慰剂对照试验,加剧一次性或重复剂量的ARO-APOC3 (10-100毫克) 进行皮下注射.
- 额外的开放标签队列包括健康的参与者和那些接受重复剂量的胆米克隆血病患者.
- 参与者被跟踪了113天,评估了安全性,APOC3,甘油三和胆固醇水平.
主要成果:
- 在10名参与者中发生过渡性,轻度至中度的肝转氨酶升高,在试验结束时消失. 没有报告与血小板狭窄相关的副作用.
- 在过高甘油血症队列中,ARO-APOC3在第113天显著降低了APOC3水平高达94.4%,高达81.2%的甘油三水平.
- 安慰剂组显示APOC3 (-1.6%) 和甘油三 (-2.8%) 的变化很小.
结论:
- 在这项短期研究中,ARO-APOC3表现出了有利的安全概况,几乎没有不良事件.
- 疗法有效地降低了健康参与者和患有过高甘油三血症的人的血清APOC3和甘油三水平.
- 需要进一步研究长期的疗效和安全性.
相关概念视频
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
02:23RNA Editing
9.0K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:22Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193